Pharmacoeconomic report: Emicizumab (Hemlibra) Hoffman-La Roche Ltd. : indication: bleeding prevention, hemophilia A.
The Health Canada indication for emicizumab includes patients with hemophilia A regardless of their disease severity, while the sponsor's submitted reimbursement request includes only severe patients and mild and moderate patients who meet specific eligibility criteria. The modelled population...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
February 2021, 2021
|
| Edition: | Final |
| Series: | CADTH drug reimbursement review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references